Roche: FDA approves Tecentriq for type of lung cancer

(CercleFinance.com) - A monoclonal antibody designed by Roche to block the interactions of tumour cells has won US approval for the treatment of people with a specific type of metastatic lung cancer, the Swiss drugmaker said on Friday.


The US Food and Drug Administration has approved Tecentriq, in combination with Avastin, another Roche drug, and chemotherapy for the initial treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations, the company said.

This approval is based on results from a phase III study, which showed that Tecentriq, in combination with Avastin and chemotherapy, helped people live significantly longer, offering patients a median overall survival of 19.2 months, it said.

Copyright (c) 2018 CercleFinance.com. All rights reserved.